A Study to Learn More About the Safety of a Single Dose of BIIB144 and How it is Processed in the Body of Healthy Adult Participants Ages 18 to 55 Years Old as Compared to a Placebo
← catalyst calendarNCT07662148 · readout in 670 d
Sponsored by Biogen (industry) · BIIB — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
48estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-21 | actual | When the study began enrolling |
| Primary completion | 2028-06-19 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-06-19 | estimated | The whole study's end, after follow-up |
| First posted | 2026-06-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteer
Interventions
- Drug: BIIB144
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFNumber of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
measured Up to Day 280
Permalink · BIIB's whole pipeline · Catalyst calendar · Every registered study · What changed